ADMA Biologics, Inc. (ADMA)

Market Cap	1.93B -58.6%
Revenue (ttm)	509.86M +11.0%
Net Income	165.35M -20.0%
EPS	0.68 -18.7%
Shares Out	231.77M
PE Ratio	12.24
Forward PE	9.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,474,637
Open	8.43
Previous Close	8.48
Day's Range	8.11 - 8.50
52-Week Range	7.21 - 22.37
Beta	0.73
Analysts	Buy
Price Target	17.60 (+111.54%)
Earnings Date	May 6, 2026

About ADMA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal anti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 647
• Stock Exchange: NASDAQ
• Ticker Symbol: ADMA
• Website: https://www.admabiologics.com

Financial Performance

In 2025, ADMA Biologics's revenue was $510.17 million, an increase of 19.63% compared to the previous year's $426.45 million. Earnings were $146.93 million, a decrease of -25.67%.

Analyst Summary

According to 5 analysts, the average rating for ADMA stock is "Buy." The 12-month stock price target is $17.6, which is an increase of 111.54% from the latest price.

Price Target

$17.6

(111.54% upside)

Analyst Consensus: Buy